Avadel Pharmaceuticals PLC (AVDL) - Total Liabilities
Based on the latest financial reports, Avadel Pharmaceuticals PLC (AVDL) has total liabilities worth $101.22 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Avadel Pharmaceuticals PLC (AVDL) net asset momentum to track the company's year-over-year net asset growth rate.
Avadel Pharmaceuticals PLC - Total Liabilities Trend (1996–2024)
This chart illustrates how Avadel Pharmaceuticals PLC's total liabilities have evolved over time, based on quarterly financial data.
Avadel Pharmaceuticals PLC Competitors by Total Liabilities
The table below lists competitors of Avadel Pharmaceuticals PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shell plc
LSE:SHEL
|
UK | GBX195.10 Billion |
|
Yantai North Andre Juice Co Ltd
SHG:605198
|
China | CN¥182.05 Million |
|
Navitas Semiconductor Corp
NASDAQ:NVTS
|
USA | $59.22 Million |
|
NORINCO International Cooperation Ltd
SHE:000065
|
China | CN¥14.38 Billion |
|
Eastern Communications Co Ltd A
SHG:600776
|
China | CN¥944.95 Million |
|
LDR Turizm AS
IS:LIDER
|
Turkey | TL3.37 Billion |
|
Werner Enterprises Inc
NASDAQ:WERN
|
USA | $1.88 Billion |
|
Energi Mega Persada Tbk
JK:ENRG
|
Indonesia | Rp926.48 Million |
Liability Composition Analysis (1996–2024)
This chart breaks down Avadel Pharmaceuticals PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AVDL market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Avadel Pharmaceuticals PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Avadel Pharmaceuticals PLC (1996–2024)
The table below shows the annual total liabilities of Avadel Pharmaceuticals PLC from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $90.39 Million | +17.45% |
| 2023-12-31 | $76.96 Million | -50.00% |
| 2022-12-31 | $153.93 Million | -8.93% |
| 2021-12-31 | $169.02 Million | +13.16% |
| 2020-12-31 | $149.37 Million | -17.31% |
| 2019-12-31 | $180.63 Million | -3.67% |
| 2018-12-31 | $187.52 Million | +11.92% |
| 2017-12-31 | $167.54 Million | -17.63% |
| 2016-12-31 | $203.41 Million | +38.27% |
| 2015-12-31 | $147.11 Million | -1.47% |
| 2014-12-31 | $149.31 Million | +18.72% |
| 2013-12-31 | $125.76 Million | +44.88% |
| 2012-12-31 | $86.81 Million | +119.17% |
| 2011-12-31 | $39.61 Million | +3.39% |
| 2010-12-31 | $38.31 Million | -22.50% |
| 2009-12-31 | $49.43 Million | +14.12% |
| 2008-12-31 | $43.31 Million | -7.40% |
| 2007-12-31 | $46.77 Million | +11.72% |
| 2006-12-31 | $41.87 Million | +11.06% |
| 2005-12-31 | $37.70 Million | +30.66% |
| 2004-12-31 | $28.85 Million | -18.02% |
| 2003-12-31 | $35.19 Million | +226.14% |
| 2002-12-31 | $10.79 Million | +1.46% |
| 2001-12-31 | $10.63 Million | +12.21% |
| 2000-12-31 | $9.48 Million | +61.93% |
| 1999-12-31 | $5.85 Million | -22.30% |
| 1998-12-31 | $7.53 Million | +4.63% |
| 1997-12-31 | $7.20 Million | +5.88% |
| 1996-12-31 | $6.80 Million | -- |
About Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name… Read more